In recent years, the main quest of science has been the pioneering of the groundbreaking biomedical strategies needed for achieving a personalized medicine. Ribonucleic acids (RNAs) are outstanding bioactive macromolecules identified as pivotal actors in regulating a wide range of biochemical pathways. The ability to intimately control the cell fate and tissue activities makes RNA-based drugs the most fascinating family of bioactive agents. However, achieving a widespread application of RNA therapeutics in humans is still a challenging feat, due to both the instability of naked RNA and the presence of biological barriers aimed at hindering the entrance of RNA into cells. Recently, material scientists’ enormous efforts have led to the development of various classes of nanostructured carriers customized to overcome these limitations. This work systematically reviews the current advances in developing the next generation of drugs based on nanotechnology-assisted RNA delivery. The features of the most used RNA molecules are presented, together with the development strategies and properties of nanostructured vehicles. Also provided is an in-depth overview of various therapeutic applications of the presented systems, including coronavirus disease vaccines and the newest trends in the field. Lastly, emerging challenges and future perspectives for nanotechnology-mediated RNA therapies are discussed.

Nanotechnology-assisted RNA delivery. From nucleic acid therapeutics to COVIDvaccines / Rinoldi, C.; Zargarian, S. S.; Nakielski, P.; Li, X.; Liguori, A.; Petronella, F.; Presutti, D.; Wang, Q.; Costantini, M.; De Sio, L.; Gualandi, C.; Ding, B.; Pierini, F.. - In: SMALL METHODS. - ISSN 2366-9608. - 5:9(2021), pp. 14-49. [10.1002/smtd.202100402]

Nanotechnology-assisted RNA delivery. From nucleic acid therapeutics to COVIDvaccines

De Sio L.;
2021

Abstract

In recent years, the main quest of science has been the pioneering of the groundbreaking biomedical strategies needed for achieving a personalized medicine. Ribonucleic acids (RNAs) are outstanding bioactive macromolecules identified as pivotal actors in regulating a wide range of biochemical pathways. The ability to intimately control the cell fate and tissue activities makes RNA-based drugs the most fascinating family of bioactive agents. However, achieving a widespread application of RNA therapeutics in humans is still a challenging feat, due to both the instability of naked RNA and the presence of biological barriers aimed at hindering the entrance of RNA into cells. Recently, material scientists’ enormous efforts have led to the development of various classes of nanostructured carriers customized to overcome these limitations. This work systematically reviews the current advances in developing the next generation of drugs based on nanotechnology-assisted RNA delivery. The features of the most used RNA molecules are presented, together with the development strategies and properties of nanostructured vehicles. Also provided is an in-depth overview of various therapeutic applications of the presented systems, including coronavirus disease vaccines and the newest trends in the field. Lastly, emerging challenges and future perspectives for nanotechnology-mediated RNA therapies are discussed.
2021
COVID-19; drug delivery; nanostructured biomaterials; personalized therapy; ribonucleic acids
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Nanotechnology-assisted RNA delivery. From nucleic acid therapeutics to COVIDvaccines / Rinoldi, C.; Zargarian, S. S.; Nakielski, P.; Li, X.; Liguori, A.; Petronella, F.; Presutti, D.; Wang, Q.; Costantini, M.; De Sio, L.; Gualandi, C.; Ding, B.; Pierini, F.. - In: SMALL METHODS. - ISSN 2366-9608. - 5:9(2021), pp. 14-49. [10.1002/smtd.202100402]
File allegati a questo prodotto
File Dimensione Formato  
Rinoldi_Nanotechnology-assisted_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 4.66 MB
Formato Adobe PDF
4.66 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1569246
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 44
social impact